These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 31189645)

  • 1. High-Plex Predictive Marker Discovery for Melanoma Immunotherapy-Treated Patients Using Digital Spatial Profiling.
    Toki MI; Merritt CR; Wong PF; Smithy JW; Kluger HM; Syrigos KN; Ong GT; Warren SE; Beechem JM; Rimm DL
    Clin Cancer Res; 2019 Sep; 25(18):5503-5512. PubMed ID: 31189645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma.
    Wong PF; Wei W; Smithy JW; Acs B; Toki MI; Blenman KRM; Zelterman D; Kluger HM; Rimm DL
    Clin Cancer Res; 2019 Apr; 25(8):2442-2449. PubMed ID: 30617133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma.
    Gupta S; McCann L; Chan YGY; Lai EW; Wei W; Wong PF; Smithy JW; Weidler J; Rhees B; Bates M; Kluger HM; Rimm DL
    J Immunother Cancer; 2019 Sep; 7(1):254. PubMed ID: 31533832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer.
    Moutafi MK; Molero M; Martinez Morilla S; Baena J; Vathiotis IA; Gavrielatou N; Castro-Labrador L; de Garibay GR; Adradas V; Orive D; Valencia K; Calvo A; Montuenga LM; Ponce Aix S; Schalper KA; Herbst RS; Paz-Ares L; Rimm DL; Zugazagoitia J
    J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma.
    Wong PF; Wei W; Gupta S; Smithy JW; Zelterman D; Kluger HM; Rimm DL
    J Immunother Cancer; 2019 Jul; 7(1):194. PubMed ID: 31337426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Non-Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling.
    Zugazagoitia J; Gupta S; Liu Y; Fuhrman K; Gettinger S; Herbst RS; Schalper KA; Rimm DL
    Clin Cancer Res; 2020 Aug; 26(16):4360-4368. PubMed ID: 32253229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.
    McLaughlin J; Han G; Schalper KA; Carvajal-Hausdorf D; Pelekanou V; Rehman J; Velcheti V; Herbst R; LoRusso P; Rimm DL
    JAMA Oncol; 2016 Jan; 2(1):46-54. PubMed ID: 26562159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarker Discovery in Patients with Immunotherapy-Treated Melanoma with Imaging Mass Cytometry.
    Martinez-Morilla S; Villarroel-Espindola F; Wong PF; Toki MI; Aung TN; Pelekanou V; Bourke-Martin B; Schalper KA; Kluger HM; Rimm DL
    Clin Cancer Res; 2021 Apr; 27(7):1987-1996. PubMed ID: 33504554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of Biomarkers of Resistance to Immune Checkpoint Blockade in NSCLC Using High-Plex Digital Spatial Profiling.
    Moutafi M; Martinez-Morilla S; Divakar P; Vathiotis I; Gavrielatou N; Aung TN; Yaghoobi V; Fernandez AI; Zugazagoitia J; Herbst RS; Schalper KA; Rimm DL
    J Thorac Oncol; 2022 Aug; 17(8):991-1001. PubMed ID: 35490853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-Plex Spatially Resolved RNA and Protein Detection Using Digital Spatial Profiling: A Technology Designed for Immuno-oncology Biomarker Discovery and Translational Research.
    Beechem JM
    Methods Mol Biol; 2020; 2055():563-583. PubMed ID: 31502169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
    Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
    Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low PD-1 Expression in Cytotoxic CD8
    Mazzaschi G; Madeddu D; Falco A; Bocchialini G; Goldoni M; Sogni F; Armani G; Lagrasta CA; Lorusso B; Mangiaracina C; Vilella R; Frati C; Alfieri R; Ampollini L; Veneziani M; Silini EM; Ardizzoni A; Urbanek K; Aversa F; Quaini F; Tiseo M
    Clin Cancer Res; 2018 Jan; 24(2):407-419. PubMed ID: 29074606
    [No Abstract]   [Full Text] [Related]  

  • 15. irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial.
    Pignon JC; Jegede O; Shukla SA; Braun DA; Horak CE; Wind-Rotolo M; Ishii Y; Catalano PJ; Grosha J; Flaifel A; Novak JS; Mahoney KM; Freeman GJ; Sharpe AH; Hodi FS; Motzer RJ; Choueiri TK; Wu CJ; Atkins MB; McDermott DF; Signoretti S
    Clin Cancer Res; 2019 Apr; 25(7):2174-2184. PubMed ID: 30670497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multispectral imaging for quantitative and compartment-specific immune infiltrates reveals distinct immune profiles that classify lung cancer patients.
    Mezheyeuski A; Bergsland CH; Backman M; Djureinovic D; Sjöblom T; Bruun J; Micke P
    J Pathol; 2018 Apr; 244(4):421-431. PubMed ID: 29282718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developing a score system to predict therapeutic outcomes to anti-PD-1 immunotherapy in metastatic melanoma.
    Indini A; Di Guardo L; Cimminiello C; Prisciandaro M; Randon G; De Braud F; Del Vecchio M
    Tumori; 2019 Dec; 105(6):465-473. PubMed ID: 31446882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer.
    Massarelli E; Lam VK; Parra ER; Rodriguez-Canales J; Behrens C; Diao L; Wang J; Blando J; Byers LA; Yanamandra N; Brett S; Morley P; Sharma P; Allison J; Wistuba II; Heymach JV
    J Immunother Cancer; 2019 Dec; 7(1):351. PubMed ID: 31843013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600.
    Massi D; Brusa D; Merelli B; Falcone C; Xue G; Carobbio A; Nassini R; Baroni G; Tamborini E; Cattaneo L; Audrito V; Deaglio S; Mandalà M
    Ann Oncol; 2015 Sep; 26(9):1980-1987. PubMed ID: 26037795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy.
    Liu Y; Zugazagoitia J; Ahmed FS; Henick BS; Gettinger SN; Herbst RS; Schalper KA; Rimm DL
    Clin Cancer Res; 2020 Feb; 26(4):970-977. PubMed ID: 31615933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.